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How Come Mary-Jane is Not on
Workers’ Comp?: Requiring Rhode
Island Workers’ Compensation
Insurers to Reimburse Employees for
Medical Marijuana
Devon Q. Toro*
INTRODUCTION

On May 20, 2019, Beacon Mutual1 (Beacon) sent a letter to
Rhode Island Senator Erin Lynch Prata regarding a proposed
amendment to include “acute pain” as one of the debilitating
conditions2 for qualification under the Edward O. Hawkins and
Thomas C. Slater Medical Marijuana Act, colloquially known
simply as the Slater Act.3 The letter was sparked by a recent influx
of employees across the country seeking medical marijuana,
perhaps in light of the opioid crisis, as a means of remedying the

* Candidate for Juris Doctor, Roger Williams University School of Law,
2021. I would like to thank my parents, Pam and John, and my sister, Quinn,
for their endless love and support. I want to give a special nod to my father for
inspiring the title of my Comment. I also want to thank my faculty advisor,
Professor Tanya Monestier, for her guidance and expertise during the writing
process.
1. Based in Rhode Island, the Beacon Mutual Insurance Company is
responsible for providing over 11,000 businesses in the state with workers’
compensation insurance. See Letter from Michael D. Lynch, Beacon Mutual
Ins. Co., to Senator Erin Lynch Prata, Chairperson, Senate Judiciary Comm.,
R.I. Senate (on file with author) (May 20, 2019).
2. 21 R.I. GEN. LAWS § 21-28.6-3(7) (laying out the “[d]ebilitating medical
conditions” a patient must have to receive medical marijuana in Rhode Island).
3. § 21-28.6-1; Lynch, supra note 1.
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effects of work-related injuries; such employees will of course seek
compensation for their out of pocket costs.4 In its letter, Beacon
expressed opposition to the proposed amendment to include acute
pain as a qualifying condition because it would open the door to a
swarm of employee workers’ compensation claims seeking medical
marijuana for pain management, given that a majority of
employees on workers’ compensation have acute pain as a side
effect of their injuries.5 Resting on arguments related to cost and
the federal prohibition of marijuana as a controlled substance,
Beacon urged the legislature either to forgo the addition of acute
pain to the list of qualifying conditions or, in the event of inclusion,
carve out an exception insulating Rhode Island workers’
compensation insurers from having to reimburse employees’ claims
seeking medical marijuana in conjunction with their work-related
injuries.6 Ultimately, the legislature declined to add acute pain to
the list of qualifying conditions and incorporated an exception
regarding workers’ compensation insurers, which states that
insurers are not required to reimburse employees for the costs
associated with the use of medical marijuana.7
This Comment analyzes the arguments both for and against
the carve out for workers’ compensation insurers in the Slater Act.
Given public policy concerns surrounding the opioid crisis, the fact
that medical marijuana is more cost-effective than other pain
management medications, and the lack of a credible threat of
federal prosecution, the Slater Act should be amended to
affirmatively require Rhode Island workers’ compensation insurers
to reimburse employees for the costs associated with medical
marijuana. So long as an employee is registered as a qualifying
patient, her injury is work-related, and her doctor opines that
medical marijuana is necessary to cure, relieve, or rehabilitate her
4. See Mack Babcock, Workers’ Compensation and Medical Marijuana:
When Will We Bridge the Gap?, WORKERS’ INJURY L. & ADVOC. GROUP, (July 16,
2019), https://www.wilg.org/?pg=WILGBlog&blAction=showEntry&blogEntry
=8525 [https://perma.cc/4B5T-N4NJ].
5. Lynch, supra note 1.
6. Id. (referring to 21 U.S.C. § 812).
7. An Act Relating to Making Appropriations in Support of FY 2020, 2019
Pub. L. R.I. ch. 88, art. 14 § 5 (amending 21 R.I. GEN. LAWS § 21-28.6-7(b)(1)).
Compare S. 830, 2019 Gen. Assemb., Jan. Sess. (R.I. 2019) (seeking to add
“acute pain” as a condition for which a person could be prescribed medical
marijuana) with § 21-28.6-3 (lacking such amendment).
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injury, the cost of medical marijuana qualifies for reimbursement
under the Rhode Island Workers’ Compensation Act.8 Workers’
compensation insurers would be completely within the bounds of
Rhode Island state law when reimbursing employees who have met
the above criteria for medical marijuana. Moreover, failure to
reimburse such employees goes against the Rhode Island Workers’
Compensation Act as written. There is nothing under Rhode Island
state law prohibiting this type of reimbursement; rather, the
legislature’s conscious decision to give workers’ compensation
insurers the choice to reimburse infers that this conduct is
consistent with state law. As described later in this Comment, this
conduct is also in conformity with federal law, thus debunking any
opposing arguments of illegality.
Part I of this Comment discusses Rhode Island’s Workers’
Compensation Act and includes an in-depth review of the statutory
requirements an employee must meet to receive benefits and
pertinent medical services. Part II details Rhode Island’s legal
status on medical marijuana, including the protections for its use
and whether patients are entitled to reimbursement, and
illuminates Beacon’s motive for opposing the amendment in the
first place. Part III analyzes various arguments for requiring
Rhode Island workers’ compensation insurers to reimburse
employees for the costs associated with medical marijuana. This
section explores both cost consideration in comparison with other
pain medications and a public policy argument favoring medical
marijuana
over
opioids.
Part
IV
addresses
various
counterarguments rooted in the federal prohibition of marijuana
and concludes that these arguments in fact lack merit. Lastly, Part
V challenges the current statute and recommends statutory reform
to require workers’ compensation insurers to affirmatively
reimburse employees for the costs of medical marijuana.
I.

THE RHODE ISLAND WORKERS’ COMPENSATION ACT

In order to qualify for workers’ compensation benefits in Rhode
Island, an injured employee must meet several statutory
requirements.9 The statute requires that the employee must be

8.
9.

See § 21-28.6-3(25); 28 R.I. GEN. LAWS § 28-33-5.
See § 28-33-1.
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injured during the course of her employment.10 An employee must
show that her injury is both work-related—sustained on the job—
and that she has an ongoing disability preventing her from
performing her regular duties.11 If an employee’s injury is not
work-related or she recovers enough to perform her regular duties,
all weekly workers’ compensation benefits are discontinued, but
medical benefits remain so long as the employee proves them
necessary to cure, relieve, or rehabilitate the effect of her injury.12
Furthermore, if the employee can prove a work-related injury and
an ongoing disability, she also is entitled to several other benefits
besides her weekly check, which only accounts for her lost earnings.
These additional benefits include dependency benefits, benefits for
scarring and loss of use, and most importantly, the reimbursement
or pre-approval of medical services and prescriptions. 13
Simply because employees are entitled to reimbursement for
medications does not necessarily mean that workers’ compensation
insurers automatically approve all requests. In most cases, the
employee must prove that the requested medication is both
“reasonable” and “necessary . . . to cure, rehabilitate or relieve the
employee from the effects of [her] injury.”14 Reasonableness is
determined based on what is accepted by doctors on a national
level.15 With regard to the “necessary” requirement, an employee
must present a doctor’s recommendation that the treatment,

10. Id. (referring to an employee who receive a “personal injury arising out
of and in the course of his or her employment, connected and referable to the
employment”).
11. See Tromba v. Harwood Mfg. Co., 177 A.2d 186, 188 (R.I. 1962) (holding
there must be “the establishment of a nexus between the injury and h[er]
employment”); see also Maresca v. Lumber Mut. Cas. Ins. Co., 107 A.2d 343,
344 (R.I. 1954) (explaining that expert testimony is used to establish extent of
injury).
12. Wright v. R.I. Super. Ct., 535 A.2d 318, 320 (R.I. 1988).
13. § 28-33-5 (providing for covered medical services); § 28-33-17(c)
(providing for dependency benefits); § 28-33-19 (providing compensation for
permanent disfigurement and loss of use); see also Mendes v. ITT Royal Elec.,
647 A.2d 1358, 1360 (R.I. 1994) (holding that employees are entitled to seek
determination from Workers’ Compensation Court regarding preauthorization of expenses for treatment to avoid situations where employees
must choose to obtain medical services without knowing in advance if insurer
will provide coverage).
14. § 28-33-5.
15. Pola v. Health-Tex, Inc., 605 A.2d 1321, 1323 (R.I. 1992).
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medical device, service, or medication is necessary to cure,
rehabilitate, or relieve her work-related injury.16 If an employee
can show that the requested medication is both reasonable and
necessary to cure, rehabilitate, or relieve her injury, the insurer
must reimburse the employee for any associated expenses. If the
insurer does not voluntarily reimburse the employee, she can file a
petition with the Rhode Island Workers’ Compensation Court,
where the judge makes the determination.17 So long as the
employee can prove both requirements, the judge will generally
require the insurer to reimburse the employee for associated
expenses; otherwise, the employee can file an appeal.18 Given that
reimbursement of medical marijuana is a relatively new issue and
judges are cognizant of the federal prohibition, there has been
hesitancy on the part of insurance companies to reimbursee
employees for the associated expenses.19
This Comment
illuminates the intricacies of both the law governing medical
marijuana and the federal prohibition in an attempt to quell any
hesitation.
II. THE SLATER ACT

Medical marijuana was legalized in Rhode Island in 2006
under the Slater Act, based on the notion that it was beneficial in
alleviating pain associated with various debilitating conditions
including glaucoma, cancer, and other chronic conditions.20
Although medical marijuana is legal in Rhode Island under the
Slater Act, patients must satisfy several statutory requirements
before they are approved for medical use.21 Medical marijuana is
only available to those who are registered “cardholders,” meaning
those who have been “registered or licensed with the department of
health or the department of business regulation pursuant to [the

16. See Geigy Chem. Corp. v. Zuckerman, 261 A.2d 844, 849 (R.I. 1970).
17. § 28-33-8(f)(1).
18. § 28-35-28(a).
19. See Babcock, supra note 4.
20. 21 R.I. GEN. LAWS § 21-28.6-1. Cannabis was only legalized for medical
use; there have been several bills since proposing recreational legalization,
none of which have passed. See generally § 21-28.6-2; Felicia Gans, Plans for
Legal Pot in R.I. Burn Out: Many Expected State to Decriminalize Recreational
Marijuana, BOS. GLOBE, June 21, 2019, at B1.
21. See § 21-28.6-4.

2020]

WORKERS’ COMPENSATION

505

Slater Act] and possess a valid registry identification card or
license.”22 In order to register as a cardholder, a Rhode Island
resident must be deemed a qualifying patient and be certified by a
practitioner as having one of the debilitating medical conditions
enumerated in the Slater Act.23
Rhode Island has never required any type of insurer, whether
it be private, state-subsidized, or workers’ compensation, to
reimburse patients for the costs associated with medical
marijuana.24 Prior to the 2019 amendment, the Slater Act carved
out an exception providing that government medical assistance
programs and private health insurers were not required to
reimburse patients for the associated costs of medical marijuana,
with no mention of workers’ compensation insurers.25 Accordingly,
while the statute’s language left discretion to governmental and
private insurers in deciding whether to reimburse patients, its
silence with regard to workers’ compensation insurers resulted in
uncertainty.26 After the amendment, the statute now affirmatively
states that workers’ compensation insurers have discretion
regarding reimbursement.27 The current statute reads as follows:
“Nothing in this chapter shall be construed to require: . . . [a]
government medical assistance program or private health insurer
or workers’ compensation insurer, workers’ compensation group self22. § 21-28.6-3(4).
23. § 21-28.6-3(25). The statute defines the term “debilitating medical
condition” as:
(i) Cancer, glaucoma, positive status for human immunodeficiency
virus, acquired immune deficiency syndrome, Hepatitis C, posttraumatic stress disorder, or the treatment of these conditions;
(ii) A chronic or debilitating disease or medical condition, or its
treatment, that produces one or more of the following: cachexia or
wasting syndrome; severe, debilitating, chronic pain; severe nausea;
seizures, including but not limited to, those characteristic of epilepsy;
or severe and persistent muscle spasms, including but not limited to,
those characteristic of multiple sclerosis or Crohn’s disease; or
agitation of Alzheimer’s Disease; or
(iii) Any other medical condition or its treatment approved by the
department of health, as provided for in § 21-28.6-5.
§ 21-28.6-3(7).
24. See § 21-28.6-7(b)(1).
25. See supra note 7.
26. See supra note 7.
27. § 21-28.6-7(b)(1).

506 ROGER WILLIAMS UNIVERSITY LAW REVIEW [Vol. 25:500
insurer, or employer self-insured for workers’ compensation
under § 28-36-1 to reimburse a person for costs associated with the
medical use of marijuana.”28
III. RHODE ISLAND WORKERS’ COMPENSATION INSURERS SHOULD BE
REQUIRED TO REIMBURSE EMPLOYEES FOR COSTS ASSOCIATED WITH
MEDICAL MARIJUANA

Rhode Island workers’ compensation insurers should be
required to reimburse employees for the costs associated with
medical marijuana to the extent necessary to relieve or rehabilitate
an employee’s work-related injury because it is more cost effective
than reimbursement of comparable pain management medications
currently reimbursed. Reimbursement also comports with public
policy concerns in light of the opioid crisis because marijuana is less
addictive than other pain-management medications.29 Further,
any hesitancy with respect to the federal prohibition is unfounded
because reimbursing employees for the costs of medical marijuana
is not a violation of the Controlled Substances Act.30 Moreover, the
federal government has expressed a disinterest in prosecuting
medical marijuana related conduct that takes place within a
comprehensive state regulatory scheme, such as Rhode Island’s
medical marijuana program.31 Based on the above, Rhode Island
workers’ compensation insurers should be required to reimburse
injured employees for the associated costs of medically necessary
medical marijuana treatment.

28. Id. (emphasis added).
29. See Hal Arkowitz & Scott O. Lilienfeld, Experts Tell the Truth About
Pot: Marijuana Use Can Be Problematic but Only Rarely Leads to Addiction,
SCI. AM.: MIND (Mar. 1, 2012), https://www. scientificamerican.com/
article/the-truth-about-pot/ [https://perma.cc/4HCG-U8YX]; see also supra
Part I (discussing criteria of treatments for coverage by workers’ compensation
insurers).
30. See infra Part IV.
31. See § 21–28.6–2(2)–(4); see also James M. Cole, Deputy Attorney
Gen., Guidance Regarding Marijuana Enforcement, 26 FED. SENT’G REP. 217,
219 (2014) (originally published Aug. 29, 2013).
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A. Reimbursement of Medical Marijuana is More Cost-Effective
than Other Pain Medications Currently Reimbursed by Rhode
Island Workers’ Compensation Insurers.
Viewed in light of all surrounding circumstances, medical
marijuana is more cost-effective than the average opioid
prescription, making it a financially beneficial pain management
substitute for insurers. Pain management refers to techniques
used to lessen someone’s pain. Pain management plays a large role
in curing, rehabilitating, and relieving employees from the effects
of work-related injuries. Techniques include physical therapy,
medication, and surgical intervention.32 No matter the chosen
route, employees partake in pain management practices to lessen
the effects of their injuries with the goal that they will eventually
return to work. The pain management technique employed,
however, depends upon the nature of the injury and the type of pain
experienced. Generally, pain is classified as either chronic or
acute.33 Unlike chronic pain, which lasts more than six months and
normally persists after an injury is fully healed, acute pain is short
in duration and dissipates when the underlying cause has been
cured.34 Prescription opioids and medical marijuana are two of the
possible pain management methods available to patients for the
treatment of chronic pain.
The average annual opioid prescription costs anywhere from
$2944 to $5840 depending on the patient’s daily dosage, which can
range from two to four tablets daily.35 When it comes to opioids,
costs of weaning must also be taken into account given the addictive
32. Pain
Management:
Non-Opioid
Treatment,
AM.
SOC.
ANESTHESIOLOGISTS, https://www.asahq.org/whensecondscount/pain-manage
ment/non-opioid-treatment/ [https://perma.cc/7GPU-L3DA] (last visited Apr.
8, 2020).
33. Acute v. Chronic Pain, CLEVELAND CLINIC (Jan. 26, 2017)
https://my.clevelandclinic.org/health/articles/12051-acute-vs-chronic-pain
[https://perma.cc/Q39Z-3JRK].
34. Id.
35. Oxycodone, CESAR (Oct. 29, 2013), http://www.cesar.umd.edu/
cesar/drugs/oxycodone.asp [https://perma.cc/3EB2-Q4GV] (“A 40mg tablet [of
OxyContin] (prescribed from a doctor) costs approximately $4 . . . . A typical
dose prescribed by a physician ranges from two to four tablets daily.”). This
figure involves Oxycodone. Oxycodone is only one of many opioid prescriptions
available to patients, so this figure may vary depending on the actual
medication prescribed.
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nature of opioids and the fact that the excess cost of treatment for
opioid use disorders can reach upwards of $5000 yearly.36 Weaning
is not only expensive, but also taxing on the employee as it often
includes methadone treatment and psychological services.37
Untreated opioid use disorders are even more costly than
weaning.38 For instance, the economic impact of untreated
addiction is felt in the criminal justice system when judicial
resources are expended in pursuit of rehabilitating addicts.39 It is
also felt in the healthcare system, where addicted persons are
treated for overdoses, and babies born dependent must be
weaned.40 Most importantly here, it is felt by employers when
previously injured employees return to the workforce less
productive than before as a result of opioid use disorders.41
Because medical marijuana mitigates the risk of opioid use
disorders and may even help patients undergoing withdrawals from
opioid addiction, there are fewer weaning expenses and economic
impacts on society.42
In Rhode Island, the average cost of medical marijuana is
roughly between $255 and $308 per ounce.43 However, under the

36. See Medications to Treat Opioids Use Disorder, NAT’L INST. ON DRUG
ABUSE, https://www.drugabuse.gov/publications/research-reports/medications
-to-treat-opioid-addiction/how-much-does-opioid-treatment-cost [https://perma
.cc/UY93-WSMU] (last visited Mar. 23, 2020).
37. Id.
38. Id.
39. See id.
40. See id.
41. See id.
42. See Beth Wiese & Adrianna, R. Wilson-Poe, Emerging Evidence for
Cannabis’ Role in Opioid Use Disorder, 3 CANNABIS & CANNABINOID RES. 179,
185 (2018). About 9% of marijuana users become addicted to marijuana; this
includes both users for medical and recreational use. Nora D. Volkow et al.,
Adverse Health Effects of Marijuana Use, NEW ENG. J. MED., 2219, 2219 (2014).
About 8–12% of opioid users become addicted; of this group about 4-6%
transition to heroin use. Opioid Overdose Crisis, NAT’L INST. ON DRUG ABUSE
(Feb. 2020), https://www.drugabuse.gov/drugs-abuse/opioids/opioid-overdosecrisis [https://perma.cc/JS5M-G3P2].
43. The Average Cost of Marijuana by State, OXFORD TREATMENT CTR. (Feb.
20, 2020),
https://www.oxfordtreatment.com/substance-abuse/marijuana/
average-cost-of-marijuana/ [https://perma.cc/3ZZ4-KM8M]. Oxford’s charts
indicate that prices in Rhode Island vary anywhere from $202 to $424. Id.
Marijuana is sold by the gram; however, price conversion is simple—one ounce
is roughly 28 grams. See Jeffery Stamberger, Marijuana Prices and Sizes,
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Slater Act, a compassion center can only dispense 2.5 ounces to a
patient within a fifteen-day period.44 With these dispensing limits,
the most a workers’ compensation insurer would be required to
reimburse an employee for a medical marijuana prescription is
somewhere between $1275 and $1540 per month.45 However, this
maximum number may not be not reflective of the actual cost a
workers’ compensation insurer would have to pay per month.46 One
study showed that the average individual dosage of marijuana for
pain is one to two marijuana cigarettes per day, with each cigarette
containing 0.5 grams of marijuana.47 Thus, an employee would use
anywhere from fifteen to thirty grams of marijuana per month,
which roughly translates to 0.5 to 1 ounce per month.48 Applying
Rhode Island’s average cost per ounce, a workers’ compensation
insurer would reimburse an average of $127 to $308 per month for
an employee, yielding a yearly cost of $2613.49 Given these figures,
the average medical marijuana prescription is significantly less
expensive than an opioid prescription. In a business where cash is
king, any saved expense is beneficial for insurers, making medical
marijuana a great option when compared with opioids. The
numbers speak for themselves—medical marijuana is a more costeffective pain medication and is ultimately less expensive for
insurers when compared with opioids. Because the cost of the
average medical marijuana prescription is lower than that of
opioids and there is no cost of weaning associated with marijuana

MEDICAL MARIJUANA, INC.
(Oct.
9,
2019),
https://www.medical
marijuanainc.com/marijuana-sizes-prices/ [https://perma.cc/5ATE-KFSZ].
44. 21 R.I. GEN. LAWS § 21–28.6–12(g)(1).
45. Calculated by multiplying the average price per ounce by two and a
half (2.5) (as that is the maximum prescription for a fifteen-day period) and
then multiplying that by two (2), as there are two (2) fifteen-day periods within
a month.
46. See Kevin P. Hill, Medical Marijuana for Treatment of Chronic Pain
and Other Medical and Psychiatric Problems: A Clinical Review, 313 JAMA
2474, 2481 (2015) (suggesting the amount of marijuana that a person would
ingest daily would be a cheaper alternative to other, opioid-based solutions).
47. Id.
48. See id.
49. This figure was calculated by multiplying the lowest average
prescription price (0.5 oz/$127.50) by twelve months and then multiplying the
highest average prescription price (1 oz/$308) by twelve months and then
averaging the two.
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use, any argument that the financial impact of reimbursement will
overburden workers’ compensation insurers is without force.
Insurers fear that by reimbursing medical marijuana, more
injured employees will seek reimbursement and drive up the cost
for insurers through a flood of claims.50 This argument is
unsupported because the pool of individuals eligible for medical
marijuana reimbursement associated with workers’ compensation
injuries is so small that there will hardly be an uptick in employees
seeking reimbursement; thus, the cost of reimbursement will be
low. Before reimbursement is even considered, the employee must
first qualify under the Slater Act, meaning that she must establish
one of the qualifying conditions and be certified by a practitioner.51
Then, the injured employee must also fulfill the statutory
requirements prescribed under the Rhode Island Workers’
Compensation Act. She would have to prove a work-related injury,
that she is disabled from her regular duties at work, and that
medical marijuana is necessary to cure, relieve, or rehabilitate the
effects of her work-related injury.52 Considering these parameters,
the universe of employees who will seek reimbursement for the cost
of medical marijuana would be lower than expected.53 As such, any
fears of the compensation floodgates opening are unwarranted.
Because the requirements for reimbursement would be
considerable and take place under a heavily regulated system, the
number of employees actually eligible would be relatively small and
already included in the pool of employees receiving alternative pain
management medications, such that workers’ compensation
insurers’ costs would remain low.

50. See Lynch, supra note 1; Mark Kraemer, How Do You Handle Medical
Marijuana Treatment for WorkComp Claims?, MINN. COMP ADVISOR (Mar. 13,
2017), http://www.minnesotacompadvisor.com/resource-center/blog/entryid/
1110/how-do-you-handle-medical-marijuana-treatment-for-workcomp-claims
[https://perma.cc/E7KE-3BFR].
51. 21 R.I. GEN. LAWS § 21-28.6-3(7).
52. 28 R.I. GEN. LAWS § 28-33-5.
53. See R.I. DEP’T OF HEALTH, 2019 MEDICAL MARIJUANA PROGRAM REPORT
TO THE RHODE ISLAND GENERAL ASSEMBLY 1 (2019). According to the Rhode
Island Department of Health, there were 17,994 active registered patients
participating in the state’s Medical Marijuana Program as of December 31,
2019. Id.
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B. Requiring Rhode Island Workers’ Compensation Insurers to
Reimburse Employees for the Cost of Medical Marijuana Favors
Public Policy in Light of the Opioid Crisis.
Reimbursing the costs of medical marijuana in the context of
workers’ compensation is favorable in light of the opioid crisis
because it would reduce the number of injured employees on
opioids, in turn reducing the number of employees who become
addicted to opioids. Prescribing medical marijuana in lieu of other
pain management medications furthers the public agenda of
combatting the opioid crisis. Opioid abuse has run rampant in the
United States for several years, claiming hundreds of thousands of
victims.54 Since the early 2000s, close to 220,000 Americans have
died as a result of opioid abuse, which has spawned a need for
alternative methods in pain management practices.55 Opioid use
disorder is especially prevalent in the realm of workers’
compensation, given that injured employees often are prescribed
pain management medications in conjunction with their workrelated injuries.56 Many workers’ compensation insurers report
that over fifty percent of claimants who have lost time out of work
as a result of their injuries have been prescribed opioids, which
indicates a drastic overprescribing rate in workers’ compensation.57
In light of the opioid crisis, insurers, medical professionals, and
patients have looked for other suitable pain-management options,
including less-potent anti-inflammatory medications, costly
physical therapy, and more invasive treatments like spinal cord
injections.58 However, none of the above-mentioned options work
as well as opioids.59 Thus there is a need for a better, safer
alternative.

54. James G. Hodge, Jr. et al., From Opioids to Marijuana: Out of the
Tunnel and into the Fog, 67 KAN. L. REV. 879, 882 (2019).
55. See id.
56. See JOSEPH PADUDA, PRESCRIPTION DRUG MANAGEMENT IN WORKERS’
COMPENSATION: THE FIFTEENTH ANNUAL SURVEY REPORT 8 (2018),
https://comppharma.com/wp-content/uploads/2018/07/2018-CompPharma-RxDrug-Mng-Survey-Public.pdf [https://perma.cc/BU3L-3V5M].
57. Id.
58. Hodge, supra note 54, at 889.
59. See id.
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Marijuana is proven to be an effective treatment for various
chronic pain conditions.60 There have been several clinical studies
analyzing the efficacy of medical marijuana in treating pain, most
of which have found it to be beneficial.61 An article evaluating
various scientific studies regarding the efficacy of medical
marijuana in relieving pain established that all studies examined
found significant pain relief.62 Moreover, scientific studies have
found that marijuana may actually be superior to opioids in
alleviating pain symptoms.63 States which have legalized medical
marijuana saw a drop in opioid-related prescriptions, indicating
that patients previously prescribed opioids found medical
marijuana to be a suitable substitute.64 Aside from its effectiveness
as a pain-reliver, marijuana has also been beneficial in treating
opioid use disorder during the weaning process.65 Not only is
medical marijuana an adequate pain management substitute for
injured employees, it is also a potential tool to combat the opioid
crisis.66
Resistance from insurers to routine medical marijuana use for
pain-management purposes stems in part from the lack of
information concerning the long-term side effects associated with
usage.67 Information regarding side effects of short-term use,
however, is more readily available.68 Those short-term effects
include impairment to cognitive functions, drowsiness, and
60. Id. at 893 (“In 2017, the National Academies found ‘substantial
evidence’ that marijuana (and its subcomponents) can also help alleviate
chronic pain.”); Annie Bach Yen Nguyen, The Alternative to Opioids:
Marijuana’s Ability to Manage Pain Caused by Injuries Sustained in the
National Football League, 19 TEX. REV. ENT. & SPORTS L. 63, 72 (2019).
Marijuana comes from the cannabis plant which contains various natural
compounds called cannabinoids. Nguyen, supra at 72. Two cannabinoids
found in the cannabis plant are “delta-9-tetrahydrocannabinol (‘THC’) and
cannabidiol (‘CBD’).” Id. While THC is known to have psychoactive effects on
the user, CBD does not. Id.
61. Nguyen, supra note 60 at 73.
62. Id.
63. Jorge Manzanares et al., Role of the Cannabinoid System in Pain
Control and Therapeutic Implications for the Management of Acute and
Chronic Pain Episodes, 4 CURRENT NEUROPHARMACOLOGY 239, 248 (2006).
64. Hodge, supra note 54, at 893.
65. Id. at 897.
66. See id.
67. See Volkow et al., supra note 42, at 2222–23.
68. See Hodge, supra note 54, at 893.
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confusion.69 There is evidence that extended medical marijuana
use may lead to various respiratory diseases or psychosis.70
However, when compared with the long-term side effects of opioid
use—which include bowel obstruction caused by chronic
constipation, sleep-disordered breathing, increased risk of
fractures, and risk of addiction—the long-term effects of marijuana
use are much more palatable.71
Requiring Rhode Island workers’ compensation insurers to
reimburse employees for out-of-pocket costs associated with
medical marijuana will save insurers money. In addition, medical
marijuana is a better alternative to other pain-management
medications—it is less expensive, less addictive, and overall a
potential solution to the opioid crisis, making it a viable substitute
given public policy concerns. Any argument that cost or healthrelated effects inhibits reimbursement is without merit. Not only
is reimbursement more cost-effective for insurers, it is better for
injured employees and, therefore, a better alternative overall.
IV. ADDRESSING THE FEDERAL PROHIBITION

In 1970, the federal Controlled Substances Act (CSA) was
introduced under the Nixon Administration as a way of
streamlining all federal laws related to drug enforcement.72 The
CSA classifies controlled substances into one of five schedules.73
Schedule determinations are based on the drug’s “accepted medical
uses, potential for abuse, and psychological and physical effects on
the body.”74 Marijuana is currently classified as a Schedule I drug,

69. Id. at 893–94; Ramsin Benyamin et al., Opioid Complications and Side
Effects, 11 PAIN PHYSICIANS S105, S105 (2008). Although there are short-term
side effects associated with marijuana use, those symptoms are more tolerable
than the short-term side effects of opioid use, which include “sedation,
dizziness, nausea, vomiting, constipation, physical dependence, tolerance, and
respiratory depression.” Benyamin et al., supra at S105.
70. Hodge, supra note 54, at 894.
71. AnGee Baldini et al., A Review of Potential Adverse Effects of LongTerm Opioid Therapy: A Practitioner’s Guide, 14 PRIMARY CARE COMPANION
FOR CNS DISORDERS (June 14, 2012).
72. Fern L. Kletter, Annotation, Construction and Application of the
Controlled Substances Act, 21 U.S.C.A. §§ 801 et seq.—U.S. Supreme Court
Cases 30 A.L.R Fed. 2d. 137, § 2 (2008).
73. Id.
74. Id.
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meaning that under the CSA, marijuana has “a high potential for
abuse,” “no current accepted medical use in treatment in the United
States,” and is not safe to use under medical supervision.75
Although marijuana is classified as a Schedule I drug under the
CSA, there are several notable declassification movements, given
the wealth of contrary scientific research and the abundance of
states that have legalized marijuana for medical and recreational
uses.76 The CSA defines several unlawful acts related to controlled
substances that are punishable at various levels, depending on the
schedule of the controlled substance at issue.77 Prohibited acts
include “manufactur[ing], distribut[ing], or dispens[ing], or
possess[ing] with the intent to manufacture, distribute, or dispense,
a controlled substance.”78 Thus, in order to be prosecuted under
the CSA, an individual would have to commit one of the abovedefined offenses.
In 2013, James M. Cole, then-Deputy Attorney General at the
United States Department of Justice, issued a memorandum (the
Cole Memo) to all United States Attorneys on the subject of
marijuana enforcement under the CSA.79
The Cole Memo
reiterates the guidance articulated in the Department of Justice’s
earlier Ogden memorandum that, going forward, due to its limited
financial resources, the Department of Justice only would focus on

75. 21 U.S.C. § 812(b)(1), (c)(I)(c)(10) (2018); contra Hodge, supra note 54,
at 893 (stating that medical marijuana is known as an effective treatment for
various illnesses according to the National Academies, which in 2017 found
there was substantial evidence that medical marijuana is effective in
alleviating chronic pain, indicating that there is an accepted use in treatment
in the United States and that it is safe to use under medical supervision (citing
NAT’L ACADS. OF SCIS. ENG’G, & MED. THE HEALTH EFFECTS OF CANNABIS AND
CANNABINOIDS: THE CURRENT STATE OF EVIDENCE AND RECOMMENDATIONS FOR
RESEARCH 87–90 (2017)).
76. See, e.g., Strengthening the Tenth Amendment Through Entrusting
States Act, S. 3032, 115th Cong. (2018). Senator Elizabeth Warren and
Senator Cory Gardner introduced the STATES Act to expressly exempt
cannabis use in legalized states from federal prosecution. President Trump
has expressed support of the bill.
77. 21 U.S.C. § 841(a).
78. § 841(a)(1). Punishable offenses also include “creat[ing], distribut[ing],
or dispens[ing], or possess[ing] with intent to distribute or dispense, a
counterfeit substance.” § 841(a)(2).
79. See Cole, supra note 31, at 217.
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Enforcement

[1] Preventing the distribution of marijuana to minors; [2]
Preventing revenue from the sale of marijuana from going
to criminal enterprises, gangs, and cartels; [3] Preventing
the diversion of marijuana from states where it is legal
under state law in some form to other states; [4] Preventing
state-authorized marijuana activity from being used as a
cover or pretext for the trafficking of other illegal drugs or
other illegal activity; [5] Preventing violence and the use of
firearms in the cultivation and distribution of marijuana;
[6] Preventing drugged driving and the exacerbation of
other adverse public health consequences associated with
marijuana use; [7] Preventing the growing of marijuana on
public lands and the attendant public safety and
environmental dangers posed by marijuana production on
public lands; and [8] Preventing marijuana possession or
use on federal property.81
Outside these eight core areas, the Cole Memo stated that the
Department of Justice will defer to state or local authorities,
confirming that there is no federal intention to prosecute outside of
the defined areas.82 Moreover, the Cole Memo afforded deference
to state and local governments in states which have legalized
marijuana in some form under comprehensive regulatory systems,
as these systems effectively eliminate threats to the general public
welfare that might arise from marijuana operations.83
At the outset of the Trump Administration, then-Attorney
General Jefferson B. Sessions III released a subsequent
memorandum (the Sessions Memo) which stated that United States
attorneys should continue to prosecute all marijuana-related
offenses.84 However, several United States Attorney’s offices have

80. Id.
81. Id. at 217–18.
82. See id.
83. Id. at 218–19.
84. Memorandum from Jefferson B. Sessions, III, Attorney Gen. on
Marijuana Enforcement to all U.S. Attorneys (Jan. 4, 2018),
https://www.justice.gov/opa/press-release/file/1022196/download
[https://
perma.cc/PFP6-X57S].
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responded with statements that they will continue to follow the
guidance in the Cole Memo, meaning that they will not prosecute
outside the eight areas of enforcement detailed therein, potentially
because there is neither the funding nor the desire to prosecute
outside of those areas.85
Furthermore, the RohrabacherBlumenauer Amendment to the federal Omnibus Spending Bill,
which became law in 2014, prohibits the Department of Justice
from spending funds to interfere with the implementation of state
medical marijuana laws.86
A. There is No Credible Threat of Federal Prosecution Under the
Controlled Substances Act Because Reimbursing Employees for
Medical Marijuana is Not Prohibited Conduct.
Those opposed to requiring Rhode Island workers’
compensation insurers to reimburse employees for expenses related
to medical marijuana point out that marijuana is still prohibited
under the CSA,87 thus raising a possible threat of federal
prosecution. However, this argument lacks merit because such
reimbursements do not fall within the scope of the CSA, which
punishes enumerated crimes such as the manufacture,
dispensation, possession, or distribution of marijuana.88 One New
Jersey workers’ compensation court judge, in response to a similar
argument, stated: “Certainly I don’t understand how [an insurance]
carrier, who will never possess, never distribute, never intend to
distribute these products, who will nearly [sic] sign a check into an
attorney’s trust account is in any way complicit with the
distribution of illicit narcotics.”89
Insurers who reimburse
employees for medical marijuana would not be manufacturing
marijuana, they would not be dispensing or distributing marijuana,
nor would they even be in possession of marijuana.90 Further,
insurers would only be issuing a reimbursement check, for a certain
85. Lawrence O. Gostin et al., Opinion, Enforcing Federal Drug Laws in
States Where Medical Marijuana is Lawful, 319 JAMA 1435, 1436 (2018).
86. Consolidated Appropriations Act, 2019, Pub. L. No. 116–6, § 537, 133
Stat. 13, 138.
87. Lynch, supra note 1.
88. 21 U.S.C. § 841(a) (2018).
89. Transcript of Record at 11, McNeary v. Freehold Township, No. 2007–
10498, 2008–8094, 2014–10233 (N.J. Workers’ Comp. Ct. June 28, 2018).
90. Id.
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amount, to the injured employee. Insurers would have no
involvement in the employee’s certification and registration in the
medical marijuana program, as that comes under the responsibility
of a medical practitioner.91 Because workers’ compensation
insurers would be committing no unlawful act under the CSA, the
argument that federal prosecution is a bar to reimbursement fails
on its face.
A dissenting opinion by Justice Joseph M. Jabar of the Maine
Supreme Judicial Court in the case of Bourgoin v. Twin Rivers
Paper Co. provides an example of the changing attitude towards the
argument that federal prosecution is an obstacle to
reimbursement.92 The dissent concludes that because the CSA only
prohibits the manufacture, dispensation, possession, and
distribution of marijuana, insurers do nothing wrong by
reimbursing an employee for the associated costs of marijuana.93
Hence, there is no conflict with the CSA because no prohibited
conduct takes place.94 As described above, the insurer simply signs
a check and does nothing else. The dissent rejected the majority’s
argument that although the insurer would not actually partake in
prohibited conduct, it would be aiding and abetting the employee’s
possession.95 The dissent found this argument unpersuasive
because a prosecutor would never be able to prove that the insurer
had the requisite mens rea to prove the offense of aiding and
abetting.96
Even if there was some violation for which insurers could be
prosecuted under the CSA, the eight enforcement priorities detailed
in the Cole Memo indicate that an attempted prosecution is highly
unlikely.97 Although the Cole Memo is no longer authoritative on
the subject, the fact remains that the Department of Justice is
limited in the manner in which it may allocate funds for marijuana

91. 21 R.I. GEN. LAWS § 21-28.6-3(30).
92. See Bourgoin v. Twin Rivers Paper Co., 187 A.3d 10, 24 (Me. 2018)
(Jabar, J., dissenting).
93. Id.
94. Id.
95. Id. at 25.
96. Id.
97. See Cole, supra note 31, at 217–18.
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enforcement;98 accordingly, some United States Attorneys have
focused prosecution efforts on larger areas of concern, such as
preventing distribution to minors, marijuana diversion, and
revenue going to criminal enterprises, gangs, and cartels.99 In the
Cole Memo, which many United States Attorneys still follow,
reimbursement of costs to a qualified state medical marijuana
program patient is not an identified enforcement area.100
Moreover, reimbursement would only occur where an employee
qualifies under the extensive requirements outlined in both the
Slater Act and the Rhode Island Workers’ Compensation Act. The
reimbursement of costs associated with medical marijuana in the
workers’ compensation context is the exact type of activity where
the federal government, under the Cole Memo, was instructed to
give deference to state authorities.101 Only under a comprehensive
scheme of regulatory measures are injured employees even able to
access medical marijuana. Employee access to medical marijuana
is further restricted based upon the quantities legally allowed
under the Slater Act, essentially eliminating any potential for
abuse.102
Thus, reimbursement for such state-sanctioned
marijuana use is exactly the type of permissible activity alluded to
in the Cole Memo.103
B. Where States Have Affirmatively Required Workers’
Compensation Insurers to Reimburse the Expenses Associated with
Medical Marijuana, No Prosecutions have Resulted.
Several states have affirmatively required workers’
compensation insurers to reimburse employees for the costs of
medical marijuana on the premise that the federal government has
no basis for prosecution because insurers commit no crime in
98. See Tom Angell, Congress Votes to Stop Feds from Enforcing
Marijuana Laws in Legal States, FORBES (June 20, 2019, 5:37 PM),
https://www.forbes.com/sites/tomangell/2019/06/20/congress-votes-to-blockfeds-from-enforcing-marijuana-laws-in-legal-states/#6687974a4b62 [https://
perma.cc/K5QJ-BA3H].
99. Gostin et al., supra note 85, at 1436; see also Cole, supra note 31, at
217–18.
100. See Cole, supra note 31, at 217–18.
101. See id. at 218–19.
102. 21 R.I. GEN. LAWS § 21-28.6-12(g)(1); see also supra notes 43–49 and
accompanying text.
103. See Cole, supra note 31, at 218–19.

2020]

WORKERS’ COMPENSATION

519

reimbursing employees.104 Currently, New Mexico has the most
case law in the area and is widely-cited by those requiring
affirmative reimbursement.105 Notable cases include Lewis v.
American General Media, Maez v. Riley Industrial, and Vialpando
v. Ben’s Automotive Services.106 In the above-mentioned cases, the
reasoning for affirmative reimbursement is two-fold. In each case,
the workers’ compensation insurer was unable to identify a statute
that it would be forced to violate.107 Thus, because there is no
articulable statutory violation, there is no threat of federal
prosecution, essentially foreclosing any argument that
reimbursement would result in illegal conduct.108 Additionally, the
court in Vialpando relied on the Cole Memo.109 The Department of
Justice has consistently stressed eight areas of enforcement
regarding marijuana and, outside of these eight areas, the
Department defers to state and local authority.110 Given that the
reimbursement of medical marijuana in the workers’ compensation
context falls outside of the areas detailed in the Cole Memo, the
court concluded that an affirmative reimbursement requirement
would result in no federal prosecutions.111 The court also
highlighted that legislative intent regarding public policy was a
factor in its decision to affirmatively require reimbursement.112

104. States affirmatively requiring reimbursement include New Mexico,
New Jersey, Connecticut, New York, and Minnesota. INS. INFO. INST., HAZE OF
CONFUSION: HOW EMPLOYERS AND INSURERS ARE AFFECTED BY A PATCHWORK OF
STATE MARIJUANA LAWS 12–13 (June 2019), https://www.iii.org/sites/
default/files/docs/pdf/marijuanaandemploy_wp_062019.pdf [https://perma.cc/
K4FH-UL49].
105. H. Scott Curtis, Cannabis & Workers’ Compensation Law, MD. B.J.,
Nov. 2017, at 24, 27.
106. Lewis v. Am. Gen. Media, 355 P.3d 850 (N.M. Ct. App. 2015); Maez v.
Riley Indus., 347 P.3d 732 (N.M. Ct. App. 2015); Vialpando v. Ben’s Auto.
Servs., 331 P.3d 975 (N.M. Ct. App. 2014).
107. See, e.g., Vialpando, 331 P.3d at 980.
108. See id. at 979.
109. Id. at 980.
110. Id.
111. See id. at 979–80.
112. Id. at 980 (“We also observe that New Mexico public policy is clear.
Our State Legislature passed the Lynn and Erin Compassionate Use Act ‘to
allow the beneficial use of medical cannabis in a regulated system for
alleviating symptoms caused by debilitating medical conditions and their
medical treatments.’”).
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Likewise, New Jersey has affirmatively required workers’
compensation insurers to reimburse employees for the costs of
medical marijuana because there is no identifiable violation of
federal law.113 In McNeary v. Freehold Township, the New Jersey
workers’ compensation court required the insurer to reimburse the
employee for two reasons.114 First, similar to the reasoning
employed in the New Mexico cases, the court concluded there is no
federal violation committed when reimbursing an employee for the
costs of medical marijuana because the insurer takes no part in any
conduct prohibited by the CSA.115 The court reasoned that a
workers’ compensation insurer does not manufacture, dispense,
distribute, or possess the marijuana at any point in the
reimbursement process.116 The insurer merely signs a check and
tenders it to the employee, thus there is no CSA violation.117
Second, the court required the insurer to reimburse the employee
under the New Jersey Workers’ Compensation Act because the
employee had proven a medical need for the marijuana in
conjunction with his work-related injury.118 Moreover, the court
referenced public policy as a reason for reimbursement, noting that
medical marijuana should be considered in light of the opioid
crisis.119
Delaware and Connecticut have also followed this trend by
affirmatively requiring workers’ compensation insurers to
reimburse employees for medical marijuana.120 Unlike New
Mexico and New Jersey, which premise reimbursement on the lack
of federal crime and prosecution, Delaware and Connecticut
analyze reimbursement under the requirements of their applicable
workers’ compensation acts.121 So long as the medical marijuana
113. Transcript of Record at 12–13, McNeary v. Freehold Township, No.
2007–10498, 2008–8094, 2014–10233 (N.J. Workers’ Comp. Ct. June 28, 2018).
114. Id. at 11.
115. Id. at 10–11.
116. Id. at 11.
117. Id.
118. See id.
119. Id.
120. Giles & Ransome v. Kalix, No. N17A-10-001 CEB, 2018 WL 4922911,
at *4 (Del. Super. Ct. Oct. 9, 2018); Petrini v. Marcus Dairy, Inc., No. 6021
CRB-7-15-7 (Conn. Workers’ Comp. Comm’n Comp. Rev. Bd. Dec. 18, 2015).
121. Giles & Ransome, 2018 WL 4922911, at *2–3; Petrini, No. 6021 CRB7-15-7.
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is medically necessary to rehabilitate the employee’s injury and the
treatment is reasonable, reimbursement is required.122 The
Connecticut review board also required patient compliance with
Connecticut’s medical marijuana law for reimbursement.123 And,
although Delaware does not expressly require patient compliance
with state medical marijuana laws, it can be inferred that
compliance with state law is also a prerequisite to
reimbursement.124 The issue of the federal prohibition is neither
argued nor mentioned by either decisionmaker in either case.125
Because there is no inquiry into the federal prohibition in either
case, one can reasonably infer that the Connecticut and Delaware
workers’ compensation courts deemed it irrelevant to disposition of
the matter.
As of January 2020, there have been no federal prosecutions of
any of the workers’ compensation insurers who have reimbursed
employees for medical marijuana costs.126 The lack of federal
prosecutions is due to the fact that there is no violation for which
the federal government can charge a workers’ compensation
insurer.127 Not only is there no violation of federal law, the
reimbursement of medical marijuana in the workers’ compensation
context falls outside of the Cole Memo enforcement priorities of the
Department of Justice.128 Furthermore, federal funds may not be
used to interfere with state medical marijuana laws which would
include cost reimbursement to qualified patients in the workers’
compensation context.129 Not only is there no legal basis for
prosecution, there are no means to prosecute.130 Given the above,

122. Giles & Ransome, 2018 WL 4922911, at *2–3; Petrini, No. 6021 CRB7-15-7.
123. See Petrini, No. 6021 CRB-7-15-7.
124. See Giles & Ransome, 2018 WL 4922911, at *4.
125. See generally Giles & Ransome, 2018 WL 4922911; see generally
Petrini, No. 6021 CRB-7-15-7.
126. An in-depth search was conducted on LexisNexis, Westlaw, and
Google. No evidence of federal prosecutions was found. Given the lack of
evidence, one can conclude that there have been no prosecutions of workers’
compensation insurers under the Controlled Substances Act for reimbursing
employees for the costs associated with medical marijuana.
127. See 21 U.S.C. § 841(a) (2018).
128. Cole, supra note 31, at 217–18.
129. Angell, supra note 98.
130. Id.
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any argument that threat of federal prosecution is an obstacle to
reimbursing employees for the costs associated with medical
marijuana is wholly without merit.
V. STATUTORY REFORM

Ultimately, the Slater Act should be amended to delete the
carve out for workers’ compensation insurers. Furthermore, the
Rhode Island Workers’ Compensation Act should be amended to
affirmatively require workers’ compensation insurers to reimburse
employees for the associated costs of medical marijuana where it is
necessary to cure, relieve, or rehabilitate their injuries. Because
the cost of medical marijuana is less expensive than that of opioids
and because medical marijuana may be a better alternative for
injured employees, reimbursement is beneficial to both insurers
and employees. Insurers would save money by reimbursing injured
employees for costs associated with medical marijuana because
such reimbursement would reduce opioid-related claims which
drive up costs. With the availability of medical marijuana,
employees would have an alternative to opioid prescriptions,
therefore decreasing the risk of addiction.
Not only should affirmative reimbursement be required, the
Rhode Island Workers’ Compensation Act should be amended to
clarify the requirements for reimbursement. Reimbursement
parameters should require the employee to fulfill the prerequisites
to register as a qualifying patient under the Slater Act and the
requirements of the Rhode Island Workers’ Compensation Act for
reimbursement of medical costs. By detailing a strict scheme for
reimbursement, workers’ compensation insurers would be
protected from unfounded claims and the compensation floodgates.
These clarifying amendments would confirm compliance with the
CSA and the Cole Memo’s federal guidance, ensuring ironclad
insulation from threat of federal prosecution for insurers.
CONCLUSION

The Rhode Island Workers’ Compensation Court’s mission is
“to provide reliable and reasonable benefits in a just and efficient
manner, with compassion and respect, to all employees who suffer
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a work-related injury.”131 Workers’ compensation insurers view
medical marijuana reimbursement through a narrow lens; that is,
in a way that only takes into account their own interests. Insurers
often fail to recognize the practical effects that reimbursement for
medical marijuana would have on injured employees. The average
workers’ compensation employee is an individual who has suffered
an injury, usually not as a result of her own fault, who is out work
receiving significantly less than her normal paycheck, and who
ultimately wants to return to work fully healed, all while trying to
find viable methods to do so. Not only is medical marijuana
reasonable and reliable, its reimbursement is beneficial to both
workers’ compensation insurers and injured employees. To deny an
injured employee, who seeks a cost-effective and legal alternative
to traditional pain management prescriptions, a chance to heal and
return to work, goes against the overall mission of the Rhode Island
Workers’ Compensation Court. As such, Rhode Island should
require workers’ compensation insurers to reimburse employees
who have been injured on the job for out-of-pocket expenses
associated with medical marijuana.

131. Workers’
Compensation Court,
RHODE ISLAND JUDICIARY,
https://www.courts.ri.gov/Courts/workerscompensationcourt/Pages/default.as
px [https://perma.cc/75WV-EXBB] (last visited Apr. 11, 2020).

